![Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis: Cancer Cell Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis: Cancer Cell](https://www.cell.com/cms/attachment/d8a0989e-9fa6-469a-9612-41e2f767cb4a/gr1_lrg.jpg)
Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis: Cancer Cell
![Pharmaceutics | Free Full-Text | Influence of Age and Sex on the Pharmacokinetics of Midazolam and the Depth of Sedation in Pediatric Patients Undergoing Minor Surgeries Pharmaceutics | Free Full-Text | Influence of Age and Sex on the Pharmacokinetics of Midazolam and the Depth of Sedation in Pediatric Patients Undergoing Minor Surgeries](https://www.mdpi.com/pharmaceutics/pharmaceutics-15-00440/article_deploy/html/images/pharmaceutics-15-00440-g002.png)
Pharmaceutics | Free Full-Text | Influence of Age and Sex on the Pharmacokinetics of Midazolam and the Depth of Sedation in Pediatric Patients Undergoing Minor Surgeries
![Oral Yohimbine as a New Probe Drug to Predict CYP2D6 Activity: Results of a Fixed-Sequence Phase I Trial | Clinical Pharmacokinetics Oral Yohimbine as a New Probe Drug to Predict CYP2D6 Activity: Results of a Fixed-Sequence Phase I Trial | Clinical Pharmacokinetics](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40262-020-00862-6/MediaObjects/40262_2020_862_Fig6_HTML.png)
Oral Yohimbine as a New Probe Drug to Predict CYP2D6 Activity: Results of a Fixed-Sequence Phase I Trial | Clinical Pharmacokinetics
![Integrative Performance Analysis of a Novel Bone Level Tapered Implant - M. Dard, S. Kuehne, M. Obrecht, M. Grandin, J. Helfenstein, B.E. Pippenger, 2016 Integrative Performance Analysis of a Novel Bone Level Tapered Implant - M. Dard, S. Kuehne, M. Obrecht, M. Grandin, J. Helfenstein, B.E. Pippenger, 2016](https://journals.sagepub.com/cms/10.1177/0022034515624443/asset/images/large/10.1177_0022034515624443-fig2.jpeg)
Integrative Performance Analysis of a Novel Bone Level Tapered Implant - M. Dard, S. Kuehne, M. Obrecht, M. Grandin, J. Helfenstein, B.E. Pippenger, 2016
![A Nanogram Dose of the CYP3A Probe Substrate Midazolam to Evaluate Drug Interactions - Halama - 2013 - Clinical Pharmacology & Therapeutics - Wiley Online Library A Nanogram Dose of the CYP3A Probe Substrate Midazolam to Evaluate Drug Interactions - Halama - 2013 - Clinical Pharmacology & Therapeutics - Wiley Online Library](https://ascpt.onlinelibrary.wiley.com/cms/asset/f0814577-bfbf-4e97-9ffb-40594b68e37a/cptclpt201327-fig-0001-m.jpg)
A Nanogram Dose of the CYP3A Probe Substrate Midazolam to Evaluate Drug Interactions - Halama - 2013 - Clinical Pharmacology & Therapeutics - Wiley Online Library
![Complement 5a Receptor deficiency does not influence adverse cardiac remodeling after pressure-overload in mice | Scientific Reports Complement 5a Receptor deficiency does not influence adverse cardiac remodeling after pressure-overload in mice | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-017-16957-3/MediaObjects/41598_2017_16957_Fig1_HTML.jpg)